Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verrica PharmaceuticalsSTU:1NE0 -0.31%49 Current Ratio is 2.10 as of Mar. 2026, which is 19% below its 10-year median of 2.59. GuruFocus rates STU:1NE0 with a GF Score™ of 49/100 and a GF Value™ of €12.16 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Verrica Pharmaceuticals ranks worse than 67.19% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Verrica Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 2.10.
Verrica Pharmaceuticals has a current ratio of 2.10. It generally indicates good short-term financial strength.
The historical rank and industry rank for Verrica Pharmaceuticals's Current Ratio or its related term are showing as below:
STU:1NE0'
s Current Ratio Range Over the Past 10 Years
Min: 1.25 Med: 2.59 Max: 40.26
Current: 2.1
During the past 10 years, Verrica Pharmaceuticals's highest Current Ratio was 40.26. The lowest was 1.25. And the median was 2.59.
STU:1NE0's Current Ratio is ranked worse than 67.19% of 1411
companies
in the Biotechnology industry
Industry Median: 3.89
vs STU:1NE0: 2.10
Verrica Pharmaceuticals (STU:1NE0) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Verrica Pharmaceuticals Current Ratio Related Terms
Verrica Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1NE0 vs ENGN, PEPG, ONCY: Current Ratio Comparison
For the Biotechnology subindustry, Verrica Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verrica Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Verrica Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verrica Pharmaceuticals (STU:1NE0) has a Current Ratio of 2.10 as of Mar. 2026. This is 19% below median its historical median of 2.59. Over the past decade, Verrica Pharmaceuticals' Current Ratio has ranged from 1.25 to 40.26. According to the industry distribution chart, Verrica Pharmaceuticals ranks #948 out of 1411 companies in the Biotechnology industry, placing it in the top 67.2%.
Is Verrica Pharmaceuticals' Current Ratio too high?
Verrica Pharmaceuticals' current Current Ratio of 2.10 is 19% below median its 10-year median of 2.59. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 40.26. The Biotechnology industry median Current Ratio is 3.89. Verrica Pharmaceuticals' value of 2.10 is 46% below this industry median. Based on the distribution chart, Verrica Pharmaceuticals ranks #948 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Verrica Pharmaceuticals has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Current Ratio compare to ENGN and PEPG?
According to the Biotechnology industry distribution chart, Verrica Pharmaceuticals ranks #948 out of 1411 companies for Current Ratio. This places Verrica Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.89. Verrica Pharmaceuticals' value of 2.10 is 46% below this benchmark. Historically, Verrica Pharmaceuticals' own Current Ratio has ranged from 1.25 to 40.26 over the past decade. While the company's 10-year median is 2.59 vs. the industry median of 3.89, Verrica Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verrica Pharmaceuticals's current Current Ratio of 2.10 is 46% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verrica Pharmaceuticals's current Current Ratio is 2.10, which is 19% below median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (STU:1NE0) is currently considered Possible Value Trap. The stock's GF Value™ is €12.16, compared to a current price of €4.86 — trading 60.1% below its estimated fair value. The current Current Ratio is 2.10, which is 19% below median its 10-year median of 2.59 and 46% below the Biotechnology industry median of 3.89. Verrica Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Verrica Pharmaceuticals (STU:1NE0), the current Current Ratio is 2.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verrica Pharmaceuticals (STU:1NE0) Overvalued in 2026?
Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.86 is trading 60.1% below its estimated GF Value™ of €12.16.
GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.
Key valuation signals for STU:1NE0:
Current Ratio: 2.10 (19% below median its 10-year median of 2.59)
GF Value™: €12.16 vs. price of €4.86 (60.1% below fair value)
Industry Position: 46% below the Biotechnology median (#948 of 1411)
No single metric tells the full story. See the STU:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
49GF Score
Get the complete analysis for STU:1NE0
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1NE0 has been successfully added to your 
